Retrospektivna analiza stope hospitalizacija bolesnika sa shizofrenijom 12 meseci pre i 12 meseci posle uključivanja jednomesečnog dugodelujućeg injekcionog paliperidon palmitata
Sažetak
Uvod/Cilj. Do sada nije bilo dostupnih publikovanih rezultata o upotrebi dugodelujućeg preparata paliperidon palmitata (PP) kod bolesnika sa shizofrenijom, lečenih u svakodnevnoj kliničkoj praksi u Republici Srbiji. Cilj rada bio je da se ispita stopa hospitalizacije bolesnika sa shizofrenijom pre i nakon uključivanja jednomesečnog dugodelujućeg injekcionog PP, kao i komplijantnost bolesnika lečenih tim lekom. Metode. Retrospektivnom studijom preseka ispitivana je stopa hospitalizacije kod 113 bolesnika sa dijagnozom shizofrenije, u periodu od 12 meseci pre uključivanja jednomesečnog dugodelujućeg injekcionog PP i 12 meseci nakon toga. U studiju su bili uključeni bolesnici starosti od 18 do 66 godina. Rezultati. Prosečna starost ispitanih bolesnika bila je 38,36 ± 11,62 godina. Među njima je 77 (68,1%) bilo muškog pola, a 36 (31,9%) ženskog pola. Od 113 bolesnika kojima je uključen PP, 78 (69,03%) bolesnika bilo je na monoterapiji, dok je 35 (30,97%) imalo dodatnu terapiju jednim oralnim antipsihotikom (risperidon, olanzapin, aripiprazol ili klozapin). Od ukupno 113 bolesnika, njih 68 (60,18%) nije bilo hospitalizovano, dok je 45 (39,82%) bolesnika bilo hospitalizovano u periodu od 12 meseci pre uključivanja jednomesečnog dugodelujućeg injekcionog PP. S obzirom na to da je od ukupno 113 bolesnika 8 isključeno sa terapije usled neželjenog događaja ili sopstvene odluke u periodu nakon uključivanja PP, analiza stope hospitalizacije posle uključivanja PP izvršena je u grupi od 105 bolesnika, od kojih je njih 9 (8,57%) bilo hospitalizovano u periodu posle uključivanja PP, a 96 (91,43%) nije. Zaključak. Naši rezultati pokazuju visoku komplijantnost bolesnika u lečenju jednomesečnim injekcionim PP i pozitivan uticaj tog leka na nisku stopu hospitalizacije bolesnika sa shizofrenijom, tokom perioda praćenja od 12 meseci. S obzirom na dostupnost PP u Republici Srbiji, ovakvi rezultati su ohrabrenje za njegovu upotrebu, kao važne terapijske opcije za lečenje bolesnika sa shizofrenijom.
Reference
1. Brohan E, Elgie R, Sartorius N, Thornicroft G; GAMIAN-Europe Study Group. Self-stigma, empowerment and perceived discrimination among people with schizophrenia in 14 European countries: the GAMIAN-Europe study. Schizophr Res 2010; 122(1–3): 232–8.
2. Republic expert committee for the development and implementation of good clinical practice guidelines. National Guide to Good Clinical Practice for diagnosing and treating schizophrenia. Belgrade: Ministry of Health of the Republic of Serbia; 2013. (Serbian)
3. Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 2020; 177(9): 868–72.
4. Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry 2022; 21(2): 295–307.
5. Lin D, Joshi K, Keenan A, Shepherd J, Bailey H, Berry M, et al. Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United States. Front Psychiatry 2021; 12: 695672.
6. Pennington M, McCrone P. The Cost of Relapse in Schizophrenia. Pharmacoeconomics 2017; 35(9): 921–36.
7. Lysaker PH, Pattison ML, Leonhardt BL, Phelps S, Vohs JL. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry 2018; 17(1): 12–23.
8. Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 2014; 4(5): 198–219.
9. Medicines and Medical Devices Agency of Serbia. Search of medicines and medical devices [Internet]. Republic of Serbia: Medicines and Medical Devices Agency of Serbia; [cited 2022 Dec 11]. Available from: https://www.alims.gov.rs/humani-lekovi/pretrazivanje-humanih-lekova/
10. U.S. Food and Drug Administration. Drug Approvals and Databases [Internet]. USA: Food and Drug Administration; [cited 2022 Dec 11]. Available from: https://www.fda.gov/drugs/
/>development-approval-process-drugs/drug-approvals-and-data
bases
11. European Medicines Agency. Medicines [Internet]. European Union: The European Medicines Agency; [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en
/medicines
12. Kane JM, McEvoy JP, Correll CU, Llorca PM. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 2021; 35(11): 1189–205.
13. Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry 2016; 77(Suppl 3): 1–24.
14. Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry 2021; 8(5): 387–404.
15. Leucht S, Samara M, Heres S, Davis JM. Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophr Bull 2016; 42(Suppl 1): S90–4.
16. Gutiérrez-Rojas L, Sánchez-Alonso S, García Dorado M, López Rengel PM. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain. CNS Drugs 2022; 36(5): 517–27.
17. Marques-Teixeira J, Amorim G, Pires AC. Results from PSIPROSPER: A multicenter retrospective study to analyze the impact of treatment with paliperidone palmitate 1-month on clinical outcomes and hospital resource utilization in adult patients with schizophrenia in Portugal. Front Psychiatry 2022; 13: 992256.
18. Devrimci-Ozguven H, Atmaca M, Baran Z, Cengisiz C, Çinar C, Erol A, et al. Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia: A Real-World Multicenter, Retrospective, Mirror-Image Study. J Clin Psychopharmacol 2019; 39(6): 604–10.
19. Fernández-Miranda JJ, Díaz-Fernández S. Tolerability of effective high doses of paliperidone palmitate in patients with severe resistant schizophrenia. Int Clin Psychopharmacol 2017; 32(1): 6–12.